Cargando…

Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers

SIMPLE SUMMARY: Early detection of ovarian cancer is a significant clinical challenge, with most women presenting with advanced stages of disease at initial diagnosis. The aim of this study was to evaluate the role of MAGEC3 and BRCA2 in epithelial ovarian cancer progression. We evaluated the effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omole, Emmanuel B., Aijaz, Iqbal, Ellegate, James, Isenhart, Emily, Desouki, Mohamed M., Mastri, Michalis, Humphrey, Kristen, Dougherty, Emily M., Rosario, Spencer R., Nastiuk, Kent L., Ohm, Joyce E., Eng, Kevin H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562635/ https://www.ncbi.nlm.nih.gov/pubmed/36230652 http://dx.doi.org/10.3390/cancers14194724

Ejemplares similares

Loss of MAGEC3 Expression Is Associated with Prognosis in Advanced Ovarian Cancers
por: Ellegate, James, et al.
Publicado: (2022)

Establishment of MAGEC2‐knockout cells and functional investigation of MAGEC2 in tumor cells
por: Wang, Jingjing, et al.
Publicado: (2016)

The MAGEC System for Spinal Lengthening in Children with Scoliosis: A NICE Medical Technology Guidance
por: Jenks, Michelle, et al.
Publicado: (2014)

The Performance of MAGEC X Spine Rods: A Comparative Retrieval Study
por: Tognini, Martina, et al.
Publicado: (2022)

MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis
por: Yang, Fan, et al.
Publicado: (2014)

The impact and surgeon perceptions of the suspension of the CE certification of MAGEC devices on clinical practice
por: Hothi, Harry
Publicado: (2022)

Sublaminar Band Fixation Provides Excellent Anchors for MAGEC Rod Distraction Systems
por: Rosenfeld, Samuel R., et al.
Publicado: (2023)

Device-Related Complications Associated with Magec Rod Usage for Distraction-Based Correction of Scoliosis
por: Agarwal, Aakash, et al.
Publicado: (2019)

Post-transcriptional regulation of cancer/testis antigen MAGEC2 expression by TRIM28 in tumor cells
por: Song, Xiao, et al.
Publicado: (2018)

MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition
por: Gu, Xuefeng, et al.
Publicado: (2019)

Identification of MAGEC2/CT10 as a High Calcium-Inducible Gene in Triple-Negative Breast Cancer
por: Beasley, Heather K., et al.
Publicado: (2022)

Tumor growth fueled by spurious senescence phenotypes
por: Mastri, Michalis, et al.
Publicado: (2019)

Study on Attenuating Angiogenesis and Epithelial–Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2
por: Jiang, Sicong, et al.
Publicado: (2018)

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene
por: Mattila, Henna, et al.
Publicado: (2011)

USP1 Regulates TAZ Protein Stability Through Ubiquitin Modifications in Breast Cancer
por: Mussell, Ashley, et al.
Publicado: (2020)

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
por: Dougherty, Brian A., et al.
Publicado: (2017)

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
por: Hodgson, Darren R., et al.
Publicado: (2018)

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
por: Birkbak, Nicolai Juul, et al.
Publicado: (2013)

Engaging Men With BRCA-Related Cancer Risks: Practical Advice for BRCA Risk Management From Male Stakeholders
por: Dean, Marleah, et al.
Publicado: (2020)

TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures
por: Sha, Kai, et al.
Publicado: (2015)

MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells
por: Yamashita, Nami, et al.
Publicado: (2023)

Metastasis to scrotal skin as the initial manifestation in a patient with rectal adenocarcinoma: a rare case report and literature review
por: Wu, Gang, et al.
Publicado: (2016)

Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation
por: Guyonnet, Emma, et al.
Publicado: (2023)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients
por: Liontos, Michalis, et al.
Publicado: (2021)

In vivo MRI volumetric measurement of prostate regression and growth in mice
por: Nastiuk, Kent L, et al.
Publicado: (2007)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Photoacoustic imaging with an acoustic lens detects prostate cancer cells labeled with PSMA-targeting near-infrared dye-conjugates
por: Dogra, Vikram, et al.
Publicado: (2016)

Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma
por: Li, Fengzhi, et al.
Publicado: (2021)

Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
por: Vaghi, Cristina, et al.
Publicado: (2020)

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study
por: Iqbal, Javaid, et al.
Publicado: (2016)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
por: Kalachand, Roshni D., et al.
Publicado: (2020)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_59bdm5g5h3nc2bnn8mhhbqrb9l